A Phase 2 interventional study of Obicetrapib in Early Alzheimer's Disease, sponsored by NewAmsterdam Pharma. Completed at 1 site in Netherlands. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-29.
Sponsored by NewAmsterdam Pharma · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Alzheimer Disease with a site in Netherlands — 17 open to participants now, 28 under way, 10 of them phase 3. Alzheimer Disease · Netherlands.
Among the 134 studies in Alzheimer Disease with a site in Netherlands, this one is the 117th largest by enrollment of the 120 interventional ones that give a count, is one of 12 that started in 2022, is one of 31 in phase 2, and was the 94th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →17 of the 134 studies in Alzheimer Disease with a site in Netherlands are open now. Recruiting first, the newest first:
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Netherlands, Australia, Austria and 14 more countries
Ages 18+
Denali Therapeutics Inc. · Sites in Netherlands, United Kingdom
Ages 18–75
Alnylam Pharmaceuticals · Sites in Netherlands, Canada, Spain and 1 more country
Ages 40–80
Alzheimercentrum Amsterdam · Sites in Netherlands
Ages 55+
Bristol-Myers Squibb · Sites in Netherlands, United States, Argentina and 14 more countries
Ages 60–85
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 46 · Phase 3 48 · Phase 4 1
First in 2000; this study’s year is marked. 12 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 246 across the 120 interventional studies, 502 across the 14 observational. Of the 99 that completed or were terminated, 45 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 134 have an industry lead sponsor. The 10 most frequent:
NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.
NewAmsterdam Pharma has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
6 of the studies in Alzheimer Disease with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06891716AC Immune SA[18F]ACI-19626 PET in TDP-43 Proteinopathies | 2026-11 |
| NCT07680335Alzheimercentrum AmsterdamThe BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease | 2026-12-31 |
| NCT03507257Indiana UniversityLongitudinal Early-onset Alzheimer's Disease Study Protocol | 2027-01-01 |
| NCT07328451Denali Therapeutics Inc.A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease | 2027-02 |
| NCT07234942Hoffmann-La RocheA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD) | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 134 studies in Alzheimer Disease with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 2a study in men and women with early Alzheimer's disease to evaluate the pharmacodynamics, pharmacokinetics and safety of obicetrapib therapy.
This study will be a proof of concept, Phase 2a study in patients with early Alzheimer's disease (clinical diagnosis of Alzheimer's disease Stage 3 or 4 based on the National Institute on Aging Alzheimer's Association Research Framework criteria) to evaluate the Pharmacodynamic, cognitive effects, Pharmacokinetic, and safety and tolerability of obicetrapib therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of neurological, psychiatric or mental conditions;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10mg obicetrapib (5mg tablets) administered orally daily for 24 weeks
Drug: Obicetrapib
10mg obicetrapib
Also known as: TA-8995
Mean Percent Change in Apolipoprotein A-I (ApoA-I) in Cerebrospinal Fluid (CSF)
Mean percent change from screening (V1) to end of treatment (V6) in ApoA-I in CSF
Time frame: 24 weeks
Mean Percent Change in Apolipoprotein A-I (ApoA-I) in Plasma
Mean percent change in ApoA-I in plasma from baseline (V2) to week 24 (V6)
Time frame: 24 weeks
Mean Percent Change in Apolipoprotein-E (ApoE) in Cerebrospinal Fluid (CSF)
Mean percent change from screening (V1) to end of treatment (V6) in ApoE
Time frame: 24 weeks
Mean Percent Change in Apolipoprotein-E (ApoE) in Plasma
Mean percent change from baseline (V2) to week 24 (V6) in plasma in ApoE
Time frame: 24 weeks
Small HDL (s-HDL) Particle Concentration in Cerebrospinal Fluid (CSF) at Baseline
Small high-density lipoprotein (s-HDL) particle concentration in cerebrospinal fluid (CSF) measured by Ion Mobility Assay (https://doi.org/10.1002/alz.12649)
Time frame: baseline
Small HDL (s-HDL) Particle Concentration in Cerebrospinal Fluid (CSF) at Week 24
Small high-density lipoprotein (s-HDL) particle concentration in CSF measured by Ion Mobility Assay (https://doi.org/10.1002/alz.12649)
Time frame: Week 24
Small HDL (s-HDL) Particle Concentration in Plasma at Baseline
Small high-density lipoprotein (s-HDL) particle concentration plasma measured by Ion Mobility Assay. For more information on the measurement used please refer to this article: https://doi.org/10.1002/alz.12649
Time frame: baseline
Small HDL (s-HDL) Particle Concentration in Plasma at Week 24
Small high-density lipoprotein (s-HDL) particle concentration in plasma measured by Ion Mobility Assay at Week 24 For more information on the measurement used please refer to this article: https://doi.org/10.1002/alz.12649
Time frame: Week 24
Mean Percent Change in Cholesterol Efflux Capacity in Cerebrospinal Fluid (CSF)
Mean percent change in cholesterol efflux capacity in CSF from screening (V1) to week 24 (V6)
Time frame: 24 weeks
| Milestone | 10mg Obicetrapib |
|---|---|
| Started | 13 |
| Completed | 13 |
| Not completed | 0 |
Mean percent change from screening (V1) to end of treatment (V6) in ApoA-I in CSF
| percent change from screening visit | 10mg Obicetrapib |
|---|---|
| Mean Percent Change in Apolipoprotein A-I (ApoA-I) in Cerebrospinal Fluid (CSF) | -8.4 ± 13.6 |
Mean percent change in ApoA-I in plasma from baseline (V2) to week 24 (V6)
| percent change from baseline | 10mg Obicetrapib Tablets |
|---|---|
| Mean Percent Change in Apolipoprotein A-I (ApoA-I) in Plasma | 37.5 ± 25.2 |
Mean percent change from screening (V1) to end of treatment (V6) in ApoE
| percent change from screening | 10mg Obicetrapib Tablets |
|---|---|
| Mean Percent Change in Apolipoprotein-E (ApoE) in Cerebrospinal Fluid (CSF) | 3.9 ± 10.3 |
Mean percent change from baseline (V2) to week 24 (V6) in plasma in ApoE
| percent change from baseline | 10mg Obicetrapib Tablets |
|---|---|
| Mean Percent Change in Apolipoprotein-E (ApoE) in Plasma | 47.8 ± 46.9 |
Small high-density lipoprotein (s-HDL) particle concentration in cerebrospinal fluid (CSF) measured by Ion Mobility Assay (https://doi.org/10.1002/alz.12649)
| average relative abundance | 10mg Obicetrapib Tablets |
|---|---|
| Small HDL (s-HDL) Particle Concentration in Cerebrospinal Fluid (CSF) at Baseline | 0.542 ± 0.138 |
Small high-density lipoprotein (s-HDL) particle concentration in CSF measured by Ion Mobility Assay (https://doi.org/10.1002/alz.12649)
| average relative abundance | 10mg Obicetrapib Tablets |
|---|---|
| Small HDL (s-HDL) Particle Concentration in Cerebrospinal Fluid (CSF) at Week 24 | 0.542 ± 0.106 |
Small high-density lipoprotein (s-HDL) particle concentration plasma measured by Ion Mobility Assay. For more information on the measurement used please refer to this article: https://doi.org/10.1002/alz.12649
No measurements were reported for this outcome.
Small high-density lipoprotein (s-HDL) particle concentration in plasma measured by Ion Mobility Assay at Week 24 For more information on the measurement used please refer to this article: https://doi.org/10.1002/alz.12649
No measurements were reported for this outcome.
Mean percent change in cholesterol efflux capacity in CSF from screening (V1) to week 24 (V6)
| percent change from screening | 10mg Obicetrapib Tablets |
|---|---|
| Mean Percent Change in Cholesterol Efflux Capacity in Cerebrospinal Fluid (CSF) | 1.9 ± 24.1 |
Collected over From first dose of study drug through Week 24.5. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 10mg Obicetrapib Tablets | 0/13 (0%) | 0/13 (0%) | 9/13 (69.2%) |
| Event | 10mg Obicetrapib Tablets |
|---|---|
| HeadacheNervous system disorders | 2/13 |
| Normocytic anemiaBlood and lymphatic system disorders | 1/13 |
| Angina pectorisCardiac disorders | 1/13 |
| Benign paroxysmal positional vertigoEar and labyrinth disorders | 1/13 |
| ConstipationGastrointestinal disorders | 1/13 |
| Loose stoolsGastrointestinal disorders | 1/13 |
| ObstipationGastrointestinal disorders | 1/13 |
| Reflux esophagitisGastrointestinal disorders | 1/13 |
| Unilateral leg swellingGeneral disorders | 1/13 |
| Covid-19Infections and infestations | 1/13 |
Baseline Population is defined as all participants who received at least one dose of study drug.
| Age, Continuous(years) | 10mg Obicetrapib |
|---|---|
| Mean | 64.5 ± 6.2 |
| Sex: Female, Male(Participants) | 10mg Obicetrapib |
|---|---|
| Female | 12 |
| Male | 1 |
| Race and Ethnicity Not Collected(Participants) | 10mg Obicetrapib |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2022 to primary completion in May 2023, 15 months.
Results were first posted in Nov 2024, 1 year 6 months after primary completion.
Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 15 months is below that.
Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TA-8995
NewAmsterdam Pharma